Prl 8 53 Buy UPD
PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine (Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.
prl 8 53 buy
The exact mechanism of action of PRL-8-53 remains unknown. Doses up to 200 mg/kg are not observed to have stimulant properties, and a dosage of 20 mg/kg does not potentiate the effects of dextroamphetamine in rats. It displays possible cholinergic properties, and potentiates dopamine while partially inhibiting serotonin. PRL-8-53 reverses the catatonic and ptotic effects of reserpine.
PRL-8-53 is relatively non-toxic, with an oral LD50 in mice of 860 mg/kg, giving the drug a high therapeutic index. Doses above 8 mg/kg have brief hypotensive effects in canines. High doses depress motor activity in the rat and mouse, with the ED50 for a 50% reduction in motor activity of mice at 160 mg/kg. PRL-8-53 displays spasmolytic effects.
It is uncertain as to exactly why PRL-8-53's development was halted. PRL-8-53 did not exhibit obvious side effects that would warrant discontinuation in animals or in its single human trial. Factors not limited to the retirement of Dr. Nikolaus Hansl in 1985 and a lawsuit filed between Hansl and Creighton University may be to blame.
On July 1, 1985 Dr. Nikolaus Hansl entered into a settlement agreement with Creighton University. The terms of the agreement guaranteed Dr. Hansl access to his laboratory facilities and office space at the university for a period of 2 years. Upon returning from a 4-month absence. Hansl found that the refrigerator he had used to store various experimental compounds had been unplugged, purportedly rendering the compounds unusable.
Researchers found that oral supplementation of PRL-8-53 was able to improve avoidance learning in rats. One human study has also been done on PRL-8-53. Each participant ingested a placebo and PRL-8-53, at separate times, in a double blind crossover study. Participants then took a memory test, consisting of twelve monosyllabic words in a particular order. The test was conducted three times, immediately after supplementation, one day after supplementation, and four days after supplementation.
People that remembered more than eight words after taking a placebo experienced minor benefits, but people over 30 or with poor short term memory benefitted greatly from supplementation. In some cases, their score on the word test doubled.
More evidence is needed to determine the ideal dosage for PRL-8-53. The effective dosage may vary, since the only human study on PRL-8-53 used a single dose of 5mg, while patent information on PRL-8-53 suggests a dosage range of 0.01-4mg/kg, with an 'ideal' range of 0.05-1.2mg/kg.
It is a nootropic research chemical derived from benzoic acid and phenylmethylamine with memory-enhancing effects, used in neuroscience research related to memory enhancement and protection against memory impairment.
The study results indicate that participants who had higher baseline scores showed the least improvement after ingesting PRL-8-53, while subjects who had demonstrated poorer initial memory or who were over 30 years of age showed significant improvement in recall.
PRL-8-53 is a largely unexplored synthetic nootropic that might have real value as a cognitive enhancer. Still, at this time, there are many more questions than answers about its safety and potential benefits.
Though it triggered strong interest when it was introduced more than 40 years ago, research on its possibilities came to a halt less than a decade after its discovery. Little has been learned about it since the study that sparked such strong interest in its potential as a memory enhancer; its optimal dosage, side effects, toxicity, interactions with other drugs, and even mechanisms of action remain unknown.
PRL-8-53 is a research chemical derived from phenylmethylamine and benzoic acid with a chemical formula of C18H21NO2. It was synthesized in the 1970s and most of the research was conducted in the 1970s. It is a nootropic compound with the studies showing properties of improving cognition and memory (Hansl and Mead, 1978).
In an earlier study scientists argued that its structure helps to interact with cholinergic receptors producing a cholinergic response in model animals. The structure of the compound helps to interact with cholinergic receptors. They function in the transduction of signals in the somatic and autonomic nervous systems, a system that controls the homeostatic environment of the body (Carlson & Kraus, 2021).
The compound potentiates dopamine which is thought to be a reason for a possible shift in the balance of neurotransmitters resulting in improved memory and cognitive function. (Hansl, 1973). Dopamine is a chemical messenger that plays an important role in the ability to think, focus, motivation, and pleasure (Schultz, 2007).
PRL-8-53 belongs to the cholinergic family of nootropic compounds. Researchers believed that the enhanced integrity of neuronal membranes involves phospholipid metabolism by such compounds (Wignall & Brown, 2014). In another article, scientists argued about effect of such cholinergic compounds to enhance memory in neurodegenerative diseases (Spiers & Hochanadel, 1999)
In an early study, at the dose of 4mg/Kg, apomorphine-induced gnawing was increased, and conditioned avoidance learning was improved in rats which indicates its function as a dopamine agonist. For each set of experiments 12-20 animals were used and conditioned avoidance learning was improved statically significant. It was also observed that PRL-8-53 also reversed catatonia and ptosis by reserpine-induced mechanism (Hansl, 1974b).
There is only one study involving humans as test subjects. In this double-blind placebo study, 47 healthy individuals were selected who were either given a 5mg dosage of PRL-8-53 or placebo, 2-2.5 hours before performing a task. To determine the effect, a verbal test of word recall was presented in an audio form to individuals. After 24 hours and then 4 days, they were instructed to write all words they can recall, preferably in a correct sequence within 5 minutes. The whole population of subjects under study were divided into subgroups according to their achievement to recall the words.
Results of this study indicated that administering 5mg of PRL-8-53 showed an improvement in acquisition and retention score which was indicated as a partial restoration of intellect, increased cognition, and improved memory. Statical analysis showed only slight significance on the acquisition, but retention improvement was quite significant with an 87-105% increase in this factor, after 24-h and 1-week retention. The group of high achievers did not show much improvement, but other sub-groups did well after administering PRL-8-53. It was nearly impossible to obtain significant improvement in this group as they have started with nearly perfect control performance.
Looking at the age factor, subjects with the age of 30 years or above showed 31 percent improvement in their responses while improvement in retention scores was around 108-152 %, after administering the 5 mg of PRL-8-53. The visual reaction showed minor improvements which are statically not significant. Furthermore, a slight improvement in motor control was observed but it did not have any statistical significance as well (Hansel and Mead, 1978).
In an earlier animal study showed an oral dose of 860 mg/kg PRL-8-53 exhibited low toxicity in mice however, dogs have tolerated the dose of 8 mg/kg without having any effect on their blood pressure while higher doses caused a drop in blood pressure for a short duration. A dose of 20 mg/kg did not cause any d-amphetamine effect in rats (Hansl, 1974a).
SelfHacked has the strictest sourcing guidelines in the health industry and we almost exclusively link to medically peer-reviewed studies, usually on PubMed. We believe that the most accurate information is found directly in the scientific source.
Our science team is put through the strictest vetting process in the health industry and we often reject applicants who have written articles for many of the largest health websites that are deemed trustworthy. Our science team must pass long technical science tests, difficult logical reasoning and reading comprehension tests. They are continually monitored by our internal peer-review process and if we see anyone making material science errors, we don't let them write for us again.
Our goal is to not have a single piece of inaccurate information on this website. If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please leave a comment or contact us at firstname.lastname@example.org.
Despite positive anecdotal experiences from some users, there is only one human study and one rat study on Prl-8-53, which were both were done in the 1970s. In addition, there currently is no ongoing research on this compound [1, 2].
In addition, some researchers suggest that Prl-8-53 may increase dopamine levels, which play a role in memory, motivation, and fatigue. It may also block serotonin production, which plays a role in anxiety, depression, and insomnia [2, 1].
Prl-8-53 has only been studied in one clinical trial that was performed in 1978, which was funded by the developer of the compound. This clinical trial was a double-blind randomized controlled study of 47 healthy adults who took a 5 mg dose of Prl-8-53 .
According to the study, those who took Prl-8-53 were able to better recall test questions in a word recollection test than the ones who took a placebo pill. Most patients were able to better recite the correct order of words up to 4 days after listening to the words .
The opinions expressed in this section are solely those of Prl-8-53 users, who may or may not have medical or scientific training. Their reviews do not represent the opinions of SelfHacked. SelfHacked does not endorse any specific product, service, or treatment. 041b061a72